Contacts

 MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report 

July 29, 2022

MedinCell (FR0004065605 – MEDCL), a pharmaceutical company at premarketing stage developing a portfolio of long-acting injectable products in various therapeutic areas, announces today the filing of its 2021/2022 Universal Registration Document (URD) with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0662.
The universal registration document notably includes:
• the annual financial report for the year ending on March 31, 2022;
• the management report;
• the CSR report;
• the report on corporate governance; and
• the proposed text of the resolutions to be submitted to the ordinary and extraordinary Shareholders’ Meeting of September 8, 2022.
This universal registration document may be consulted on the Company’s website (invest.medincell.com), “Investors” section, and on the AMF’s website (www.amf-france.org).

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.